Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐ras status for unresectable colorectal liver metastasis (BECK study)

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 8, 2015-08 ,pp. : 634-645

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma

By  

Oncology Research and Treatment, Vol. 34, Iss. 7, 2011-06 ,pp. : 368-376

Karger

Access to resources Recommend Favorite

Assessment of a Drug-Eluting Balloon for the Treatment of de novo Coronary Lesions Guided by Optical Coherence Tomography: Study Protocol for a Randomized Controlled Trial

By  

Cardiology, Vol. 136, Iss. 4, 2016-11 ,pp. : 252-257

Karger

Access to resources Recommend Favorite

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 61-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvant Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases

By  

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 637-643

Karger

Access to resources Recommend Favorite